|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Phase 2a Trial Results: Promising Gene Therapy for Overactive Bladder - URO-902 Safety and Efficacy Evaluation
|
|
Kenneth Peters, MD
|
| Ken Peters joins Diane Newman to present the results of a Phase 2a trial evaluating the safety and efficacy of URO-902, an investigational gene therapy for overactive bladder. URO-902 is a plasma vector that expresses the alpha subunit of the human BK channel, which reduces bladder overactivity and leads to detrusor relaxation.
|
|
|
|
|
|
|
|
|
|
|
|
|
Developing A Novel Neuromodulation Therapy for Treating Overactive Bladder
|
|
Anne Agur, Ph.D.
|
| Diane Newman is joined by Anne Agur to share how they collect data to develop novel models of the human saphenous nerve. These novel models of the human saphenous nerve will be used to develop neuromodulation therapy approaches, both an engineering finite element approach, and for clinicians to look at electrode placement.
|
|
|
|
|
|
|
|
|
|
|
|
|
Mechanistic Pathway Through Which Saphenous Nerve Stimulation Can Modulate Bladder Function
|
|
Paul Yoo, Ph.D., PEng
|
| Joining Diane Newman is Paul Yoo to discuss saphenous nerve stimulation. In this particular study, Dr. Yoo's lab was interested in the mechanistic pathway through which saphenous nerve stimulation can modulate bladder function, and how this could be translated to patients with overactive bladder.
|
|
|
|
|
|
|
|
|
|
|
|
| Growing Old with an Overactive Bladder
|
| Diane Newman, DNP, CRNP, FAAN, BCB-PMD
|
| Diane Newman discusses a patient case and management of a 77-year-old woman with overactive bladder (OAB) and worsening symptoms presented challenges in medication selection due to potential side effects, especially cognitive effects, associated with antimuscarinic OAB drugs in older adults. Given the patient's age, the clinician opted for mirabegron, a β3-adrenoceptor agonist, as an alternative to antimuscarinics, aiming to minimize the risk of adverse cognitive effects.
|
|
|
|
|
|
| Efficacy And Safety Of A Novel Gene Therapy (URO-902; PVAX/HSLO) In Female Patients With Overactive Bladder Syndrome And Urgency Urinary Incontinence: Results From A Phase 2a Trial
|
| Kenneth Peters, MD
|
| Kenneth Peters presents on URO-902, a gene therapy involving intradetrusor injection for overactive bladder (OAB). URO-902 demonstrated promising results in a 12-week interim analysis of a 48-week phase 2a trial. The study involved adult women with OAB and urgent urinary incontinence who were insufficiently managed with oral OAB medications.
|
|
|
|
|
|
|
|
|
|
|
| Intradetrusor OnabotulinumtoxinA Injections at the Time of Holmium Laser Enucleation of the Prostate for Men with Overactive Bladder Symptoms - Beyond the Abstract
|
| Nicholas Dean, MD, Mitchell Huang, MD, and Amy Krambeck, MD
|
| In a retrospective study exploring patient recovery after laser enucleation of the prostate (HoLEP), concurrent intradetrusor OnabotulinumtoxinA (OTA) injections were offered to men with urge incontinence requiring daily pads. The study observed that patients receiving OTA alongside HoLEP did not experience negative impacts on peri-operative or post-operative outcomes.
|
|
|
|
|
|
| The Choice of a Therapeutic Agent in Female Overactive Bladder Patients in Real-World Practice - Beyond the Abstract
|
| Hiroshi Masuda, MD
|
| In a retrospective study of overactive bladder (OAB) patients in Japan, researchers aimed to understand the factors influencing the choice between anticholinergic drugs and β3 adrenergic agonists, both recommended as first-line treatments. The study, involving 109 patients, found that choices between these medications often lacked clear indicators or guidelines, relying on the treating doctor's preferences and experience.
|
|
|
|
|
|
| A 3D Digital Map of the Human Saphenous Nerve: A Neuroanatomical Approach to Developing a Novel Neuromodulation Therapy for Treating Overactive Bladder
|
| Michael Peng, MD, Paul Yoo, Ph.D., PEng, Anne Agur, Ph.D.
|
| A study aimed at developing a neuromodulation therapy for overactive bladder (OAB) created a 3D digital map of the human saphenous nerve (SAFN) and its branches. Using lower limb specimens, the researchers digitized and laser-scanned the SAFN and its branches, modeling them in 3D. The map revealed the extensive subcutaneous network of the SAFN, particularly the infrapatellar and medial crural cutaneous branches, which include anterior and posterior branches that supply the medial aspect of the leg.
|
|
|
|
|
|
| The Bladder Inhibitory Effects of Saphenous Nerve Stimulation are Mediated Via a Supraspinal Pathway in Anesthetized Rodents
|
| Grant Gruenspan, Jian Wang, Laureen Hachem, Michael Fehlings, Paul Yoo
|
| This study investigated the mechanistic pathway of saphenous nerve (SAFN) stimulation in inhibiting bladder responses in anesthetized rodents. The research aimed to understand how SAFN stimulation affects bladder function, particularly the bladder contraction rate (BCR) and the incidence of overflow incontinence.
|
|
|
|
|
|
|
|
|
|
|
